: iStockAnalyst.com Symbols Feed

A Busy Month For Immunogen (Part II)

Thu, 03 Dec 2009 21:03:11 GMT

At ASH 2009, Immunogen (IMGN) and its partners will present clinical data on three compounds: Sanofi-Aventis’ (SNY) SAR3419, Immunogen’s IMGN901 and Biotest’s BT-062.[More...]

The Clock Is Ticking On Micromet (MITI)

Tue, 25 Aug 2009 00:05:20 GMT

Earlier this month, Micromet (MITI) concluded an impressive public offering of $75M, approximately 20% of the company’s market cap. The offering illustrates the transformation the company has undergone from an anonymous biotech play into a recognized industry leader. This is also echoed by the growing attention from Wall St. When I first wrote about Micromet in 2007, the company was covered by a single analyst,[More...]

FDA Calendar Updates: MITI, KERX, GSK, DYAX, ARNA, PGNX

Mon, 08 Jun 2009 22:30:23 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of about 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response lett (...)[More...]

Top Picks For ASCO 2009

Tue, 26 May 2009 11:44:28 GMT

The ASCO annual meeting, one of the most important events in the pharmaceutical industry will take place in Orlando next weekend. With over 4,000 abstracts to be presented this year, separating the wheat from the chaff is difficult, but below is an incomp[More...]

Micromet (Nasdaq: MITI) – More Reasons For Optimism

Sun, 10 May 2009 17:03:16 GMT

Two weeks ago, Micromet (MITI) hosted its annual R&D day, where it discussed plans for 2009 and beyond.[More...]

Morphosys – A Biotech Rule Breaker

Tue, 31 Mar 2009 20:40:00 GMT

Morphosys (MOR.DE) is one of the most unusual biotech companies, as it breaks three basic rules that apply to drug development companies:

We are pleased that Micromet has been added to the Russell 3000 Index and expect that it will increase our visibility in the investment community," said Buck Phillips, Senior Vice President and Chief Financial Officer of Micromet.

[More...]

Phase 1 Study Initiated with Micromet Anti-GM-CS Human Antibody MT203

Thu, 18 Jun 2009 10:56:00 GMT

Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced the initiation of the first clinical trial for the anti-granulocyte macrophage colony-stimulating factor human antibody MT203 by its collaboration partner Nycomed.[More...]

Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients

Mon, 08 Jun 2009 10:57:00 GMT

German Multicenter ALL Study Group Presented Data at the 14th Congress of the European Hematology Association Showing High Response Rate in Patients with Minimal Residual Disease[More...]